BLFS
BLFS, Aroon Indicator entered an Uptrend on Sep 21, 2020Over the last three days, Tickeron A.I.dvisor has detected that BLFS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 239 similar cases, 211 of which were successful. Based on this data, the odds of success are 88%. Current price $27.05 is above $19.22 the highest support line found by Tickeron A.I. Throughout the month of 08/20/20 - 09/22/20, the price experienced a +37% Uptrend, while the week of 09/15/20 - 09/22/20 shows a -3% Downtrend.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BLFS just turned positive on August 26, 2020. Looking at past instances where BLFS's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +16.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in 245 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. Tickeron AI detected that in 211 of 239 cases where BLFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
BLFS LONGThis is a solid stock and is very undersold. My opinion is its a great buy under $18 for a swing trade with target around $24 or long term holding.
BLFS GOING FOR ONE MORE WAVE UP?BLFS is trading into a range. Now it's in the lower range. If the lower dotted line holds i'm expecting a breakout to the upside. This is an abstract of the news: "BOTHELL, Wash., Aug. 24, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science."
